TEST mBANK mFOR mFOCUSmONmNURSINGmPHARMACOLOGY m7THEDITION mBYmKARCH
, Stuvia.comm-
mThemMarketplacemto mBuy mand mSell myour mStudy mMaterial
Chapterm1:mIntroductionmto mDrugs
CognitivemLevel:m ApplicationmDiffic
ulty:m Moderate
Integrated mProcess:m Nursingmprocess
1.A mnursemworkingminmradiologymadministersmiodinemtomampatient mwhomismhavingmamco
mputerized maxialmtomographym(CAT)mscan.mAmnursemworkingmonmanmoncologymunit m
administersmchemotherapymtompatientsmwhomhavemcancer.mAt mthemPublicmHealthmDep
artment,mamnursemadministersmammeasles-mumps-rubellam (MMR)mvaccinemtomam14-
mmonth-
old mchild masmamroutinemimmunization.mWhichmbranchmof mpharmacologymbest mdescrib
esmthemactionsmof mallmthreemnurses?
A) Pharmacoeconomics
B) Pharmacotherapeutics
C) Pharmacodynamics
D) Pharmacokinetics
Ans: B
Response:
Pharmacologymismthemstudymof mthembiologicmeffectsmof mchemicals.mNursesmareminvolve
d mwithmclinicalmpharmacologymormpharmacotherapeutics,mwhichm isma mbranchmof mpharm
acologymthat mdealsmwithmthemusesmof mdrugsmtomtreat,mprevent,mand mdiagnosemdisease.mT
hemnursemworkingminmradiologymismadministeringmamdrugmtomhelpmdiagnosema mdisease.mT
hemnursemworkingmonmanmoncologymunit mismadministeringmamdrugmtomhelpmtreat mamdiseas
e.mPharmacoeconomicsmincludesmanymcostsminvolved minmdrugmtherapy.
Pharmacodynamicsminvolvesmhowmamdrugmaffectsmthembody,mand mpharmacokineticsmis
mhow mthembodymactsmonmthemdrug.
CognitivemLevel:mComprehensionmD
ifficulty:mEasy
Integrated mProcess:m Nursingmprocess
2.A mphysicianmhasmordered mintramuscularminjectionsmof mmorphine, mamnarcotic, meverym4 m
hoursmasmneeded mformpainmformammotormvehiclemaccident mvictim.mThemnursemismawaremth
at mtheremismamhighmabusempotentialmformthismdrug;mtherefore,mmorphinemismcategorized ma
sma:
A) SchedulemI mdrug
B) SchedulemII mdrug
C) SchedulemIII mdrug
D) SchedulemIVmdrug
Ans: B
Response:
Narcoticsmsuchmasmmorphinemaremconsidered mschedulemII mdrugsmbecausemof mthemhighma
busempotentialmwithmseveremdependencemliability.mSchedulemI mdrugsmhavemhighmabusem
potentialmand mnomaccepted mmedicalmuse.mSchedulemIII mdrugsmhavemamlessermabusempote
ntialmthanmschedulemII mdrugsmand manmaccepted mmedicalmuse.mSchedulemIV mdrugsmhaveml
owmabusempotentialmand mlimited mdependencemliability.
CognitivemLevel:mComprehensionmD
ifficulty:mEasy
Integrated mProcess:m Communicationmand mdocumentation
3.A mnursemworkingmformamdrugmcompanymisminvolved minmphasemIII mdrugmevaluationmstudie
s.mWhichmof mthemfollowingmmight mthemnursembemresponsiblemformduringmthismstagemof md
rugmdevelopment?
, Chapterm1:mIntroductionmto mDru
gs
A) Workingmwithmanimalsmwhomaremgivenmexperimentalmdrugs
B) Monitoringmdrugmeffectsminmpatientsmwhomaremselected mtomparticipateminmamstud
y,mwhomhavemthemdiseasemthat mthemdrugmismmeant mtomtreat
C) Collectingmrecordsmof msymptomsmthat mparticipantsmexperiencemwhilemtaking
mamdrugmand mdeterminingmwhethermtheymaremcaused mbymthemdiseasemormthemdr
ug
D) Informingmhealthy,myoungmvolunteermparticipantsmof mpossiblemrisksmthat mcoul
d moccurmfrommtakingmanmexperimentalmdrug
Ans: C
Response:
PhasemIII mstudiesminvolvemusemof mamdrugminmamvast mclinicalmmarket mwherempatientsmarem
asked mtomrecord manymsymptomsmtheymexperiencemwhilemtakingmthemdrugs.mNursesmmaym
bemresponsiblemformhelpingmcollect mand manalyzemtheminformationmtombemshared mwithmth
em Food mand mDrugmAdministrationm(FDA).mUsemof manimalsminmdrugmtestingmismdoneminm
thempreclinicalmtrials.mAmselect mgroupmof mpatientsmwhomareminvolved minmphasemII mstudie
smparticipateminmstudiesmwheremthemparticipantsmhavemthemdiseasemthemdrugmismintended m
tomtreat.mThesempatientsmaremmonitored mcloselymformdrugmeffects.mPhasemI mstudiesminvol
vemhealthymhumanmvolunteersmwhomaremusuallympaid mformtheirmparticipation.mNursesmm
aymobservemformadversemeffectsmand mtoxicity.
CognitivemLevel:mComprehensionmD
ifficulty:m Moderate
Integrated mProcess:m NursingmProcess
4. Whichmof mthemfollowingmconceptsmismconsidered mwhenmgenericmdrugsmaremsubstituted mf
ormbrand-namemdrugs?
A) Bioavailability
B) Criticalmconcentration
C) Distribution
D) Half-life
Ans: A
Response:
Bioavailabilitymismthemportionmof mamdosemof mamdrugmthat mreachesmthemsystemicmcirculati
onmand mismavailablemtomact monmbodymcells.mBindersmused minmamgenericmdrugmmaymnot mbe
mthemsamemasmthosemused minmthembrand-
namemdrug.mTherefore,mthemwaymthembodymbreaksmdownmand musesmthemdrugmmaymdiffer,
mwhichmmaymeliminatemamsubstitution.mCriticalmconcentrationmis mthemamount mof mamdrugm
that mismneeded mtomcausemamtherapeuticmeffect.
Distributionmismthemphasemof mpharmacokineticsmthat minvolvesmthemmovement mof mamdrugm
tomthembody'smtissues.mAmdrug'smhalf-
lifemismthemtimemit mtakesmformthemamount mof mdrugmtomdecreasemtomone-
half mof mthempeakmlevel.
CognitivemLevel:m AnalysismDifficult
y:m Difficult
Integrated mProcess:m Teaching/learning
5. Amnursemismteachingmhermpatient mabout mthemusemof mover-the-
counterm(OTC)mdrugs.mWhichmof mthemfollowingmstatementsmbest minformsmthempatient ma
bout mtheirmsafemuse?
A) ―OTCmdrugsmaremproductsmthat maremavailablemwithout mprescriptionmformsel
f-mtreatment mof mminormcomplaints.‖
B) ―OTCmdrugsmaremconsidered mmedicationsmand mshould mbemreported monmamdr
ugmhistory.‖
, Chapterm1:mIntroductionmto mDru
gs
C) ―OTCmdrugsmweremapproved masmprescription mdrugsmbut mlatermweremfound mtom
bemsafemwithout mthemneed mformamprescription.‖
D) ―OTCmdrugsmneed mtombemtakenmwithmcaution.mTheymcanmmaskmthemsignsma
nd msymptomsmof manmunderlyingmdiseasemand minterferemwithmprescriptionm
drugmtherapy.‖
Ans: D
Response:
OTCmdrugsmaremconsidered mmedicationsmand mshould mbemreported.mOTCmdrugsmaremavai
lablemwithout mamprescription,malthoughmsomemweremfirst mapproved masmprescriptionmdrug
s.mThemmost mimportant mteachingmshould mrelatemtomtheirmsafemusemand mthat mOTCmdrugsmc
anmmaskmsymptomsmof mdiseasemand minterferemwithmprescribed mdrugs.
CognitivemLevel:mKnowledgemDiffic
ulty:mEasy
Integrated mProcess:m NursingmProcess
6. Whichmof mthemfollowingmlegislativemactsmallowed mthemFood mand mDrugmAdministrati
onm(FDA)mtomtightenmcontrolmovermthemqualitymof mdrugsmand mrequired mthat msafetyma
nd mefficacymstandardsmbemestablished?
A) PuremFood mand mDrugmAct mof m1906
B) FederalmFood,mDrug,mand mCosmeticmAct mof m1938
C) DurhammHumphreymAmendment mof m1951
D) Kefauver-HarrismAct mof m1962
Ans: D
Response:
ThemKefauver-
HarrismAct mwasmthemresult mof mthemusemof mthem1960smdrugmthalidomidem(Thalomid).mThe
mpublicmconcernmled mtomthemlegislationmthat mgavemthemFDA mregulatorymcontrolmovermtes
tingmand mevaluatingmof mdrugsmand mallowed mit mtomset mstandardsmformefficacymand msafety.
mThemPuremFood mand mDrugmAct mrequired mlabelingmtomeliminatemfalsemclaims.mThemFede
ralmFood,mDrug,mand mCosmeticmAct mgavemthemFDA mthempowermtomenforcemstandardsmfo
rmtestingmdrugmtoxicitymand mmonitoringmlabeling.mThemDurham-
mHumphreymAmendment menforced mprescriptionsmformdistribution.
CognitivemLevel:m ApplicationmDiffic
ulty:m Moderate
Integrated mProcess:m Teaching/learning
7. Amnursemisminstructingmampregnant mpatient mconcerningmthempotentialmriskmtomhermfet
usmfrommampregnancymcategorymBmdrug.mThemnursemwould minformmthempatient mthat
:
A) ―Adequatemstudiesminmpregnant mwomenmhavemdemonstrated mtheremismnomriskmtomt
hemfetus.‖
B) ―Animalmstudiesmhavemnot mdemonstrated mamriskmtomthemfetusmbut mtheremhavembe
enmnomadequatemstudiesminmpregnant mwomen.‖
C) ―Animalmstudiesmhavemshownmanmadversemeffect monmthemfetusmbut mtheremarem
nomadequatemstudiesminmpregnant mwomen.‖
D) ―Theremismevidencemof mhumanmfetalmriskmbut mthempotentialmbenefitsmfrommusemof mt
hemdrugmmaymbemacceptablemdespitempotentialmrisks.‖
Ans: B
Response:
CategorymBmindicatesmthat manimalmstudiesmhavemnot mdemonstrated mamriskmtomthemfetusmbut
, Stuvia.comm-
mThemMarketplacemto mBuy mand mSell myour mStudy mMaterial
Chapterm1:mIntroductionmto mDrugs
CognitivemLevel:m ApplicationmDiffic
ulty:m Moderate
Integrated mProcess:m Nursingmprocess
1.A mnursemworkingminmradiologymadministersmiodinemtomampatient mwhomismhavingmamco
mputerized maxialmtomographym(CAT)mscan.mAmnursemworkingmonmanmoncologymunit m
administersmchemotherapymtompatientsmwhomhavemcancer.mAt mthemPublicmHealthmDep
artment,mamnursemadministersmammeasles-mumps-rubellam (MMR)mvaccinemtomam14-
mmonth-
old mchild masmamroutinemimmunization.mWhichmbranchmof mpharmacologymbest mdescrib
esmthemactionsmof mallmthreemnurses?
A) Pharmacoeconomics
B) Pharmacotherapeutics
C) Pharmacodynamics
D) Pharmacokinetics
Ans: B
Response:
Pharmacologymismthemstudymof mthembiologicmeffectsmof mchemicals.mNursesmareminvolve
d mwithmclinicalmpharmacologymormpharmacotherapeutics,mwhichm isma mbranchmof mpharm
acologymthat mdealsmwithmthemusesmof mdrugsmtomtreat,mprevent,mand mdiagnosemdisease.mT
hemnursemworkingminmradiologymismadministeringmamdrugmtomhelpmdiagnosema mdisease.mT
hemnursemworkingmonmanmoncologymunit mismadministeringmamdrugmtomhelpmtreat mamdiseas
e.mPharmacoeconomicsmincludesmanymcostsminvolved minmdrugmtherapy.
Pharmacodynamicsminvolvesmhowmamdrugmaffectsmthembody,mand mpharmacokineticsmis
mhow mthembodymactsmonmthemdrug.
CognitivemLevel:mComprehensionmD
ifficulty:mEasy
Integrated mProcess:m Nursingmprocess
2.A mphysicianmhasmordered mintramuscularminjectionsmof mmorphine, mamnarcotic, meverym4 m
hoursmasmneeded mformpainmformammotormvehiclemaccident mvictim.mThemnursemismawaremth
at mtheremismamhighmabusempotentialmformthismdrug;mtherefore,mmorphinemismcategorized ma
sma:
A) SchedulemI mdrug
B) SchedulemII mdrug
C) SchedulemIII mdrug
D) SchedulemIVmdrug
Ans: B
Response:
Narcoticsmsuchmasmmorphinemaremconsidered mschedulemII mdrugsmbecausemof mthemhighma
busempotentialmwithmseveremdependencemliability.mSchedulemI mdrugsmhavemhighmabusem
potentialmand mnomaccepted mmedicalmuse.mSchedulemIII mdrugsmhavemamlessermabusempote
ntialmthanmschedulemII mdrugsmand manmaccepted mmedicalmuse.mSchedulemIV mdrugsmhaveml
owmabusempotentialmand mlimited mdependencemliability.
CognitivemLevel:mComprehensionmD
ifficulty:mEasy
Integrated mProcess:m Communicationmand mdocumentation
3.A mnursemworkingmformamdrugmcompanymisminvolved minmphasemIII mdrugmevaluationmstudie
s.mWhichmof mthemfollowingmmight mthemnursembemresponsiblemformduringmthismstagemof md
rugmdevelopment?
, Chapterm1:mIntroductionmto mDru
gs
A) Workingmwithmanimalsmwhomaremgivenmexperimentalmdrugs
B) Monitoringmdrugmeffectsminmpatientsmwhomaremselected mtomparticipateminmamstud
y,mwhomhavemthemdiseasemthat mthemdrugmismmeant mtomtreat
C) Collectingmrecordsmof msymptomsmthat mparticipantsmexperiencemwhilemtaking
mamdrugmand mdeterminingmwhethermtheymaremcaused mbymthemdiseasemormthemdr
ug
D) Informingmhealthy,myoungmvolunteermparticipantsmof mpossiblemrisksmthat mcoul
d moccurmfrommtakingmanmexperimentalmdrug
Ans: C
Response:
PhasemIII mstudiesminvolvemusemof mamdrugminmamvast mclinicalmmarket mwherempatientsmarem
asked mtomrecord manymsymptomsmtheymexperiencemwhilemtakingmthemdrugs.mNursesmmaym
bemresponsiblemformhelpingmcollect mand manalyzemtheminformationmtombemshared mwithmth
em Food mand mDrugmAdministrationm(FDA).mUsemof manimalsminmdrugmtestingmismdoneminm
thempreclinicalmtrials.mAmselect mgroupmof mpatientsmwhomareminvolved minmphasemII mstudie
smparticipateminmstudiesmwheremthemparticipantsmhavemthemdiseasemthemdrugmismintended m
tomtreat.mThesempatientsmaremmonitored mcloselymformdrugmeffects.mPhasemI mstudiesminvol
vemhealthymhumanmvolunteersmwhomaremusuallympaid mformtheirmparticipation.mNursesmm
aymobservemformadversemeffectsmand mtoxicity.
CognitivemLevel:mComprehensionmD
ifficulty:m Moderate
Integrated mProcess:m NursingmProcess
4. Whichmof mthemfollowingmconceptsmismconsidered mwhenmgenericmdrugsmaremsubstituted mf
ormbrand-namemdrugs?
A) Bioavailability
B) Criticalmconcentration
C) Distribution
D) Half-life
Ans: A
Response:
Bioavailabilitymismthemportionmof mamdosemof mamdrugmthat mreachesmthemsystemicmcirculati
onmand mismavailablemtomact monmbodymcells.mBindersmused minmamgenericmdrugmmaymnot mbe
mthemsamemasmthosemused minmthembrand-
namemdrug.mTherefore,mthemwaymthembodymbreaksmdownmand musesmthemdrugmmaymdiffer,
mwhichmmaymeliminatemamsubstitution.mCriticalmconcentrationmis mthemamount mof mamdrugm
that mismneeded mtomcausemamtherapeuticmeffect.
Distributionmismthemphasemof mpharmacokineticsmthat minvolvesmthemmovement mof mamdrugm
tomthembody'smtissues.mAmdrug'smhalf-
lifemismthemtimemit mtakesmformthemamount mof mdrugmtomdecreasemtomone-
half mof mthempeakmlevel.
CognitivemLevel:m AnalysismDifficult
y:m Difficult
Integrated mProcess:m Teaching/learning
5. Amnursemismteachingmhermpatient mabout mthemusemof mover-the-
counterm(OTC)mdrugs.mWhichmof mthemfollowingmstatementsmbest minformsmthempatient ma
bout mtheirmsafemuse?
A) ―OTCmdrugsmaremproductsmthat maremavailablemwithout mprescriptionmformsel
f-mtreatment mof mminormcomplaints.‖
B) ―OTCmdrugsmaremconsidered mmedicationsmand mshould mbemreported monmamdr
ugmhistory.‖
, Chapterm1:mIntroductionmto mDru
gs
C) ―OTCmdrugsmweremapproved masmprescription mdrugsmbut mlatermweremfound mtom
bemsafemwithout mthemneed mformamprescription.‖
D) ―OTCmdrugsmneed mtombemtakenmwithmcaution.mTheymcanmmaskmthemsignsma
nd msymptomsmof manmunderlyingmdiseasemand minterferemwithmprescriptionm
drugmtherapy.‖
Ans: D
Response:
OTCmdrugsmaremconsidered mmedicationsmand mshould mbemreported.mOTCmdrugsmaremavai
lablemwithout mamprescription,malthoughmsomemweremfirst mapproved masmprescriptionmdrug
s.mThemmost mimportant mteachingmshould mrelatemtomtheirmsafemusemand mthat mOTCmdrugsmc
anmmaskmsymptomsmof mdiseasemand minterferemwithmprescribed mdrugs.
CognitivemLevel:mKnowledgemDiffic
ulty:mEasy
Integrated mProcess:m NursingmProcess
6. Whichmof mthemfollowingmlegislativemactsmallowed mthemFood mand mDrugmAdministrati
onm(FDA)mtomtightenmcontrolmovermthemqualitymof mdrugsmand mrequired mthat msafetyma
nd mefficacymstandardsmbemestablished?
A) PuremFood mand mDrugmAct mof m1906
B) FederalmFood,mDrug,mand mCosmeticmAct mof m1938
C) DurhammHumphreymAmendment mof m1951
D) Kefauver-HarrismAct mof m1962
Ans: D
Response:
ThemKefauver-
HarrismAct mwasmthemresult mof mthemusemof mthem1960smdrugmthalidomidem(Thalomid).mThe
mpublicmconcernmled mtomthemlegislationmthat mgavemthemFDA mregulatorymcontrolmovermtes
tingmand mevaluatingmof mdrugsmand mallowed mit mtomset mstandardsmformefficacymand msafety.
mThemPuremFood mand mDrugmAct mrequired mlabelingmtomeliminatemfalsemclaims.mThemFede
ralmFood,mDrug,mand mCosmeticmAct mgavemthemFDA mthempowermtomenforcemstandardsmfo
rmtestingmdrugmtoxicitymand mmonitoringmlabeling.mThemDurham-
mHumphreymAmendment menforced mprescriptionsmformdistribution.
CognitivemLevel:m ApplicationmDiffic
ulty:m Moderate
Integrated mProcess:m Teaching/learning
7. Amnursemisminstructingmampregnant mpatient mconcerningmthempotentialmriskmtomhermfet
usmfrommampregnancymcategorymBmdrug.mThemnursemwould minformmthempatient mthat
:
A) ―Adequatemstudiesminmpregnant mwomenmhavemdemonstrated mtheremismnomriskmtomt
hemfetus.‖
B) ―Animalmstudiesmhavemnot mdemonstrated mamriskmtomthemfetusmbut mtheremhavembe
enmnomadequatemstudiesminmpregnant mwomen.‖
C) ―Animalmstudiesmhavemshownmanmadversemeffect monmthemfetusmbut mtheremarem
nomadequatemstudiesminmpregnant mwomen.‖
D) ―Theremismevidencemof mhumanmfetalmriskmbut mthempotentialmbenefitsmfrommusemof mt
hemdrugmmaymbemacceptablemdespitempotentialmrisks.‖
Ans: B
Response:
CategorymBmindicatesmthat manimalmstudiesmhavemnot mdemonstrated mamriskmtomthemfetusmbut
